Dynavax (DVAX) Tops Q3 EPS by 14c; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
November 2, 2023 4:01 PM EDTGenerated quarterly HEPLISAV-B® vaccine net product revenue of $62.3 million, a 66% year-over-year increaseRaising full year HEPLISAV-B net product revenue guidance to $210 - $220 million, compared to prior range of $200 - $215 millionCash and investments increased to $720 million at quarter end; expects positive free cash flow for full yearConference call today at 4:30 p.m. ET/1:30 p.m. PT
EMERYVILLE, Calif., Nov. 2, 2023 /PRNewswire/... More
